Lipidtargeted therapies what should be added to statins. Hps2thrive randomized placebocontrolled trial in 25 673 high. It remains unknown whether this translates to increased risk of serious statinassociated adverse events amongst chinese patients. Merck announced today that the hps2thrive heart protection study 2 treatment of hdl to reduce the incidence of vascular events study. Hps2thrive the heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2thrive, with more than 40,000 patients, was the largest cardiovascular outcomes trial of lipidmodifying therapy to date.
Although no data have suggested that the lowdensity lipoproteincholesterol ldlc increases associated with some omega3 fatty acid formulations lead to adverse outcomes, these elevations in ldlc levels may compromise the achievement of lipid targets. Interven7on in metabolic syndrome with low hdlhigh triglycerides. The spl will be accessible from publicly available labeling repositories. However, the understanding from genetic studies and negative results from randomised trials that low hdl cholesterol might not cause cardiovascular disease as originally thought has now generated renewed. Also within 14 days, amend all pending supplemental. Randomized placebocontrolled trial of er niacin and laropriprant in 25,673 patients with preexisting cardiovascular disease acc 20. Improving outcomes in patients with ascvd with pcsk9 inhibitors robert p giugliano, md, sm senior investigator, timi study group. Methods and results prior to randomization, 42424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required.
Listing a study does not mean it has been evaluated by the u. The evidence to support this practice has been murky, with insufficient data to support a benefit in clinically meaningful outcomes. Funded by nhlbi, abbott laboratories kos, merck, inc. Streamlining safety data collection in hospitalacquired. Conclusionsin hps2thrive, the addition of extendedrelease niacin laropiprant to statinbased therapy reduced quality of lifeadjusted survival and. Hps2thrive was a randomized, doubleblind, multicenter trial that enrolled patients at 245 sites in the united kingdom 89 sites, scandinavia 84, and china 72. Clinicians treating high risk patients who have a less than anticipated response to statins, who are unable to tolerate a less than recommended intensity of a statin or who are completely statin intolerant, may consider the. Data analysis plan for assessing clinical efficacy and. Triglycerides and cardiovascular disease the lancet.
Clinician perspective on the benefits of niacin therapy. Over 25,000 patients with preexisting cardiovascular disease from the uk, scandinavia and china were recruited into hps2 thrive. Information on submitting spl files using elist may be found in the guidance for industry titled. Statincentric versus lowdensity lipoproteincentric. In hps2 thrive, a large placebocontrolled trial of 25,673 highrisk patients, chinese patients taking simvastatin 40 mg had a higher absolute risk of myopathy than patients in europe. Hps2 thrive treatment of hdl to reduce the incidence of vascular events concluded that adding er niacinlaropiprant to current standard treatment did not produce worthwhile reductions in the risk of heart attacks, strokes and operations to open blocked arteries. But before long, i found that i had real difficulty divorcing myself completely from the. No benefit in the hps2 thrive population with half of the patients having low hdlc. Primary prevention most people are not treated until after their first mi. Hps2thrive treatment of hdl to reduce the incidence of vascular events. Despite improvements in diagnosis and management, atherosclerotic cardiovascular disease ascvd remains a leading cause of morbidity and mortality in the us, responsible for one in three deaths. Treatment of hdl to reduce the incidence of vascular events author. Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their lowdensity lipoprotein. Hps2thrive showed that er niacinlaropiprant does not reduce the risk of heart attacks and strokes and furthermore it does increase the risk of side effects.
Hps2 thrive is a large randomized trial assessing the effects of extended release er niacin in patients at high risk of vascular events. No benefit in the hps2thrive population with half of the patients having low hdlc exception. Treattotarget may result in suboptimal evidencebased statin therapy or increased risk of adverse events. Rxfiles drug comparison charts 10th edition oct 2014. Phd director of the national biobank centre for cvd codirector of china oxford centre for international health research nccd, sklcd, fuwai hospital may 05th, 2012, rome, italy. Data analysis plan for assessing clinical efficacy and safety of er niacinlaropiprant in the hps2 thrive trial 1 background this data analysis plan describes the strategy, rationale and statistical methods that will guide assessment of the clinical efficacy and safety of er niacinlaropiprant in the hps2 thrive trial. The agenda start by making you the patient cardiovascular risk reduction, diabetes, infectious diseases, a variety of symptomatic conditions including heartburn, acute pain etc. The heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2thrive study was a randomized, multicenter, doubleblind, prospective, controlled clinical trial that recruited patients at 245 sites in the united kingdom, scandinavia, and china and was published in the new england journal of medicine in july 2014. Triglyceridelowering therapies reduce cardiovascular disease. Niacin the first lipidmodifying drug what have we learnt. Now that hps2thrive and improveit are out, dont we have to change the guidelines. Data analysis plan for assessing clinical efficacy and safety. Leaders in managing lipids for improved cardiovascular health. Second, some outcomes were assessed with hospital diagnosis codes, and milder forms of adverse events may have been missed.
Effects of extendedrelease niacin with laropiprant in. The emergence of multidrugresistant mdr, gramnegative pathogens in hospitals is an increasing threat to public health, and in recent decades, the approval of antibacterial therapies in the united states and europe, among other countries, has lagged considerably. Outcomes and the hps2 thrive treatment of hdl to reduce the incidence of vascular events studies. The results of hps2thrive led to the withdrawal of er niacin laropiprant from the. Hps2 thrive randomized placebocontrolled trial in 25 673 highrisk patients of er niacinlaropiprant. Bryan brewer from medstar research institute and atherosclerosis research, jeanclaude tardif from the research center of the montreal heart institute, and peter p. Triglyceridelowering therapies reduce cardiovascular.
Treatment of hdl to reduce the incidence of vascular events keywords. Comparison between aimhigh and hps2 thrive comments on hps2 thrive. Several organizations and initiatives have begun to publicize the global crisis of mdr bacteria to foster support for. The role of hdlc in the management of atherosclerosis the. Combining the outcomes of hps2 thrive with the negative outcomes of trials of novel agents that increase hdl cholesterol eg, torcetrapib in illuminate and dalcetrabib in daloutcomes suggest that the previous understanding of hdl as an independent risk factor for chd is incorrect or is an oversimplification of the complex molecules true role.
Nonstatin lipidlowering agents m holler last updated. Background compared to caucasians, chinese achieve a higher blood concentration of statin for a given dose. The results of hps2thrive led to the withdrawal of er niacinlaropiprant from the. Managing cholesterol and pursuing a healthier lifestyle. No benefit in the aimhigh general population of low hdlc patients. Accaha cvd prevention guidelines understanding risk. Challenges and opportunities for large clinical research. Major coronary event nonfatal mi or coronary death. Philosophy once you know the evidence decision making. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, or a smaller reporting company. Comparison hps2thrive and aimhigh trial aimhigh trial n engl j med 2011 hps2thrive trial hps2thrive clinical outcome data presentation expected in 20 prerandomisation phase with erniacin 2g laropiprant exclusion.
Effects of vascular and nonvascular adverse events. For the past four decades, the concentration of cholesterol contained in highdensity lipoprotein hdl particles has been a major focus of research and a target for potential prevention opportunities. Hps2thrive treatment of hdl to reduce the incidence of vascular events concluded that adding er niacinlaropiprant to current standard treatment did not produce worthwhile reductions in the risk of heart attacks, strokes and operations to open blocked arteries. Evolving roles of nonstatin and newer drugs article pdf available in drugs 7511 july 2015 with 203 reads how we measure reads. Clinician perspective on the benefits of niacin therapy for. For that matter, some experts are questioning whether increasing hdlc levels has a. Bradley bale of the grace clinic and texas tech health science center and amy doneen from the heart attack and stroke prevention center, spokane, wa and texas tech.
Conclusionsin hps2thrive, the addition of extendedrelease niacinlaropiprant to statinbased therapy reduced quality of lifeadjusted survival and. I had even stopped taking my own self prescribed niacin 2,500 mg twice a day, which i had been religiously consuming for over 2 decades. No annoying ads, no download limits, enjoy it and dont forget to bookmark and share the love. Clinicians treating high risk patients who have a less than anticipated response to statins, who are unable to tolerate a less than recommended intensity of a statin or. Esc congress 2012 cardiology congress cardiovascular disease created date. Niacin and hdl cholesterol time to face facts donald m. The hps2thrive study was a large multinational, placebocontrolled, randomised.
An external file that holds a picture, illustration, etc. Now that hps2 thrive and improveit are out, dont we have to change the guidelines. Challenges and opportunities for large clinical research in china. The following expert roundtable discussion was held on november, 2011. In hps2 thrive, the er niacin was combined with a new drug called laropiprant which is a prostaglandin receptor blocker in order to reduce problems due to flushing. Hps2 thrive randomized placebocontrolled trial in 25673 highrisk patients of er niacin laropiprant.
Rader from the university of pennsylvania moderated the topic the role of hdlc in the management of atherosclerosis with drs. Looking forward to 2018 heart and stroke clinical update. On this course, you will learn how to design and run streamlined, efficient trials to provide reliable answers which change practice. Based on findings from aimhigh and hps2 thrive trials, and given its potential for side effects, niacin now appears not to be helpful in the management of hyperlipidemia beyond having the potential for increasing hdlc. Challenges and opportunities for large clinical research in china lixin jiang md. Secondary prevention residual risk on statin treatment is substantial 7075% of coronary events still occur. You can download the following thrive study documents. Hps2thrive randomized placebocontrolled trial in 25673. Hps2thrive randomized placebocontrolled trial in 25673 highrisk patients of er niacin laropiprant. Hps2thrive is a large randomized trial assessing the effects of extended release er niacin in patients at high risk of vascular events. A randomized trial of the longterm clinical effects of raising hdl cholesterol with extended release niacinlaropiprant.
The role of hdlc in the management of atherosclerosis. Products containing omega3 fatty acids, such as krill oil and fish oils, have been effective in lowering triglyceride levels. Hps2thrive randomized placebo controlled trial in 25 673 highrisk patients of. Treatment of hdl to reduce the incidence of vascular events. New drugs for lipid osu center for continuing medical education. Hps2 thrive collaborative group hps2 thrive randomized placebocontrolled trial in 25 673 highrisk patients of er niacinlaropiprant. Rearrange individual pages or entire files in the desired order. Hps2thrive treatment of hdl to reduce the incidence of. Hps2 thrive heart protection study 2treatment of hdl to reduce the incidence of vascular events jelis japan epa lipid intervention study marine multicenter, placebocontrolled, randomized, doubleblind, 12week study with an openlabel extension omega effect of omega 3fatty acids on the. Hps2 thrive heart protection study 2 treatment of hdl to reduce the incidence of vascular events. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in rule 12b2 of the. The study also found that using er niacinlaropiprant did cause sideeffects.
Get reliable answers designing and running streamlined randomized trials are you planning or running a randomized trial. The hps2 thrive investigators, led by dr jane armitage oxford university, uk, randomized 25 673 patients with vascular disease to 2 g of extendedrelease niacin and 40 mg. Treatment of hdl to reduce the incidence of vascular events hps2. Hps2thrive is a large randomized trial assessing the effects of extended. Among patients with atherosclerotic disease on statin. Esceas guidelines for the management of dyslipidaemias.
Hps2thrive aims to find out whether by combining niacin a drug that has been available for 50 years with a new drug laropiprantwhich reduces the. Apr 18, 2007 treatment of hdl to reduce the incidence of vascular events hps2 thrive hps2 thrive the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Cardiovascular outcomes trials of fibrates, niacin, or omega3 fatty acids alone, or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically significant clinical benefits have been reported in subgroups with elevated triglycerides tg andor elevated tg plus low highdensity lipoprotein cholesterol hdlc. Hps2thrive heart protection study 2treatment of hdl to reduce the incidence of vascular events jelis japan epa lipid intervention study marine multicenter, placebocontrolled, randomized, doubleblind, 12week study with an openlabel extension omega effect of omega 3fatty acids on the. Acoi 2019 fish oils swimming in a new direction jeffrey s. Methods we conducted a populationbased retrospective cohort study of older adults mean age, 74 years newly prescribed a statin in ontario, canada between. After the introduction of statins, clinical emphasis first focussed on ldl cholesterollowering, then on the potential for raising hdl cholesterol, with less focus on lowering triglycerides. Hps2thrive randomized placebocontrolled trial in 25 673 highrisk patients of.
Freeman do facoi fnla professor of internal medicine chairman division endocrinology and metabolism. Hps2 thrive the heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2 thrive, with more than 40,000 patients, was the largest cardiovascular outcomes trial of lipidmodifying therapy to date. Leaders in managing lipids for improved cardiovascular health investor presentation june 2015. The primary aim of hps2thrive is to assess the effect of er niacin 2 g plus. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in. In our opinion, these 2 studniacin in the treatment of hyperlipidemias in light of new clinical trials.
Current combination therapy on top of statins for ldl lowering bile acid sequestrants. Bradley bale of the grace clinic and texas tech health science center and amy doneen from the heart attack and stroke prevention center, spokane. Niacin in the treatment of hyperlipidemias in light of new. As of today we have 76,952,453 ebooks for you to download for free. In aimhigh, benefit seen in high tg, low hdlc subset population. Jones from the baylor college of medicine moderated the topic clinician perspective on the benefits of niacin therapy for the treatment of dyslipidemia and strategies to improve longterm adherence to therapy with dr. Longterm care updates for years, niacin and fibrates have been recommended as addon therapy to statin treatment in patients not meeting their lipid goals. New drugs for lipid osu center for continuing medical. While little data are available right now and the press release contains scant information, boden noted that hps2 thrive was an allcomers secondaryprevention study and did not preselect patients.
812 306 812 1058 314 593 654 357 987 830 816 798 1172 1002 1012 254 1437 998 1280 692 438 253 1004 206 154 1226 71 374 80 1254 609 914 809 616 1323 433 704 826 1035 1290 70 1213